Personalis Inc (PSNL) Actualités

Form 8-K - Current report

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Personalis and Tempus Expand Collaboration to Biopharma

Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Personalis Reports Third Quarter 2024 Financial Results

41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash...

Form 8-K - Current report

Personalis to Present at the Stifel 2024 Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at...

Personalis to Announce Third Quarter 2024 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial...

Form 8-K - Current report

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Results continue to demonstrate the importance of ultra-sensitive ctDNA detection in lung cancer and immunotherapy Personalis, Inc. (Nasdaq:...